Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Replication protein A 32 kDa subunit (RPA32, also known as RPA2) is a critical component of the heterotrimeric replication protein A (RPA) complex, which also includes the 70 kDa subunit (RPA1) and the 14 kDa subunit (RPA3). RPA32 contains an N-terminal flexible domain, a central oligonucleotide/oligosaccharide-binding (OB) fold DNA-binding domain (DBD D), and a C-terminal protein interaction domain. The central DNA-binding domain is essential for viability, supporting the structural and protein-protein interaction roles necessary for DNA replication, repair, and recombination. RPA32 can be phosphorylated, particularly at its N-terminal domain, which modulates protein interactions and the DNA damage response, linking it to cell cycle regulation and checkpoint control. Loss or dysfunction of RPA32, or its complex, leads to impaired DNA metabolism and cell viability, and its dysregulation is implicated in cancer and genomic instability disorders. RPA32 is not typically considered a classical drug target, but it is essential for cellular responses to genotoxic stress, and is under study as a potential therapeutic vulnerability in cancer, with phosphorylated RPA32 providing a readout for DNA checkpoint activation.
Inhibition of single-stranded DNA binding by the RPA complex; Disruption of protein-protein interactions essential for DNA replication and repair; Modulation of phosphorylation status to alter DNA repair pathway choice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Replication protein A 32 kDa subunit (RPA32).